SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCOS.L Regulatory News (COS)

  • There is currently no data for COS

Director/PDMR Shareholding

8 Aug 2019 10:53

RNS Number : 4195I
Collagen Solutions PLC
08 August 2019
Β 

Β 

8 August 2019

Β 

Collagen Solutions plc

("Collagen Solutions" or the "Company")

Β 

Director / PDMR Dealing

Β 

The Company today announces that, Jamal Rushdy, Chief Executive Officer ("CEO") of the Company,Β was granted options (the "Options") over 2,025,000 ordinaryΒ sharesΒ of 1 penceΒ eachΒ inΒ the ordinary shareΒ capitalΒ ofΒ theΒ CompanyΒ ("Shares") exercisable at a price of 3.9 pence per Share.

Β 

The Options will vest in three equal tranches on the first, second and third anniversaries of the date of grant. Such vesting will be conditional on his continued employment. In addition, the ability to exercise any vested Options will be dependent on achieving a closing middle market price per Share of 10 pence at any time after the date of grant and on the Company delivering sustainable positive cash flows from operations for any period of six months. All Options will lapse after 10 years from the date of grant, being 7 August 2029.

Β 

NotificationΒ andΒ publicΒ disclosureΒ ofΒ transactionsΒ byΒ personsΒ dischargingΒ managerialΒ responsibilitiesΒ andΒ personsΒ closelyΒ associatedΒ withΒ them

Β 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Jamal Rushdy

2

Reason for the notification

Β 

a)

Position/status

Chief Executive Officer

b)

Initial notification /Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Collagen Solutions Plc

b)

LEI

213800IFY1CVGRGETL95

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Β 

Β 

Identification code

Ordinary shares of 1p each

Β 

Β 

Β 

ISIN Code: GB00B94T6Y14

b)

Nature of the transaction

Grant of options over ordinary shares of 1p each exercisable at 3.9p per share

c)

Price(s) and volume(s)

Β 

Price(s): Volume(s):

Β 

0 pence 2,025,000

Β 

Aggregated information

Β 

Β 

- Aggregated volume

Β 

Β 

- Price

Β 

Β 

Β 

N/A

Β 

Β 

N/A

e)

Date of the transaction

08/08/2019

f)

Place of the transaction

Outside a trading venue

Β 

Β 

For further information please contact:

Β 

Collagen Solutions Plc

Β 

Jamal Rushdy, CEOΒ 

Via Walbrook

Hilary Spence, CFO

Β 

Β 

Β 

Cenkos Securities Plc (Nominated Adviser and Broker)

Β 

Giles Balleny

Tel: 0207 397 8900

Stephen Keys

Β 

Β 

Β 

Walbrook PR Ltd

Tel: 020 7933 8780 or collagen@walbrookpr.com

Anna Dunphy

Mob: 07876 741 001

Β 

Β 

Β Β Β Β 

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHCKFDPCBKKKFK
Date   Source Headline
30th Aug 201711:21 amRNSResult of AGM
30th Aug 20177:00 amRNSAGM Statement
26th Jul 20177:00 amRNSPosting of Annual Report & notice of AGM
25th Jul 201711:36 amRNSDirector/PDMR Shareholding
25th Jul 20177:15 amRNSHardman Research: Transition to sustainable growth
13th Jul 201711:39 amRNSDirector/PDMR Shareholding
11th Jul 20177:00 amRNSFinal Results
7th Jul 20177:00 amRNSFirst patient enrolment in ChondroMimetic® study
19th Jun 20177:00 amRNSNotice of Results
13th Jun 20177:00 amRNSProvisional patent submitted
11th May 20177:15 amRNSHardman Research: Trading:earnings above forecasts
25th Apr 20177:00 amRNSTrading Update
24th Apr 20177:00 amRNSConsolidation of US R&D activities & Board change
10th Apr 20177:00 amRNSCollagen Based Spray Adhesive Poster Presented
3rd Apr 201711:22 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSAgreement signed with Smart Matrix Limited
31st Mar 20174:52 pmRNSHolding(s) in Company
29th Mar 20177:00 amRNSPericardium Divisional Patent in Australia
27th Mar 201712:39 pmRNSDirector/PDMR Shareholding
24th Mar 20179:26 amRNSDirector/PDMR Shareholding
23rd Mar 20177:00 amRNSAttending UK Investor Show
20th Mar 20178:56 amRNSIntroduces new online sales initiative in the US
15th Mar 20179:58 amRNSHolding(s) in Company
14th Mar 20173:28 pmRNSHolding(s) in Company
13th Mar 201711:52 amRNSHardman Research: Engineering cartilage repairs
13th Mar 20179:57 amRNSHolding(s) in Company
13th Mar 20177:05 amRNSHardman Research: Engineering cartilage repairs
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSHolding(s) in Company
9th Mar 20177:00 amRNSAttending AAOS and ORS meetings in San Diego
8th Mar 20177:00 amRNSDirector/PDMR Shareholding
7th Mar 20174:08 pmRNSHolding(s) in Company
7th Mar 20171:01 pmRNSDirector/PDMR Shareholding
7th Mar 201711:19 amRNSHolding(s) in Company
7th Mar 20179:56 amRNSHolding(s) in Company
6th Mar 20172:24 pmRNSResult of General Meeting
20th Feb 20177:00 amRNSInvestor presentation
15th Feb 201711:29 amRNSGrant of Options
14th Feb 201711:24 amRNSHardman Research: Funding accelerated growth
14th Feb 20177:00 amRNSPlacing Open Offer and Debt Financing
7th Feb 20177:00 amRNSAttends MD&M West Conference in Anaheim
19th Jan 20177:00 amRNSNew Scientific Advisory Board appointments
13th Jan 20177:00 amRNSThird Medical Research Scotland Ph.D. Studentship
21st Dec 201612:06 pmRNSHardman Research: Foundations for strategic growth
19th Dec 20167:00 amRNSHalf-year Report
14th Dec 20167:00 amRNSPoster Presentation at TERMIS-AM
2nd Dec 20167:00 amRNSNotice of Results
13th Oct 20167:00 amRNSTrading Statement
3rd Oct 20167:00 amRNSChange of Adviser
15th Sep 20167:00 amRNSParticipation in major Horizon 2020 project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.